Scientists are in the early stages of developing biomarkers for non-Alzheimer’s neurodegenerative diseases. At the Tau Global Conference, researchers presented promising preliminary data for a new tau PET biomarker that is sensitive to non-Alzheimer’s forms of tau tangles, and another cerebrospinal fluid assay that could help diagnose a rare form of dementia called progressive supranuclear palsy. If these tests pan out, a new test may reach the market within five years, though exact estimates are difficult to make.